Precision cancer therapies provide advanced options for lymphoma patients

Lymphoma is a blood cancer that develops in the lymphatic system, part of the body's means of fighting infection. At The University of Kansas Cancer Center in Kansas City, we offer deep experience and leading treatment options – including revolutionary immunotherapy treatments – to provide care for patients who are fighting lymphoma.

Like leukemia, lymphoma is a blood cancer, but unlike leukemia, which grows in the blood-forming cells inside bone marrow, lymphoma originates in the lymphocytes, which fight infection. There are more than 40 recognized subtypes of lymphoma. Each of these has a distinct biology, natural history, and importantly, different treatment options. Lymphoma is generally quite responsive to treatment and many types of lymphoma are curable.

Early diagnosis is critical to achieving the best possible outcome. The first step in caring for you begins the moment you call.  

• Complex care for lymphomas requires advanced expertise. At The University of Kansas Cancer Center, our lymphoma specialists are leaders in lymphoma care. We only treat patients who have lymphoma and provide the latest in diagnosis, treatment and resources. Because of this expertise, each patient gets the right treatment at the right time for their disease.
• We use the latest technologies and diagnostic tools to obtain an accurate diagnosis and deliver effective treatment. Molecular testing is performed on-site. Given the complex nature of lymphoma, getting the correct diagnosis is critical to having a good outcome.
• We provide customized, coordinated care. Every patient is unique, with unique circumstances and unique goals. Our doctors, nurses and other staff collaborate closely to develop the treatment plan that best suits your needs and communicate frequently to remain up to date on patients’ care and progress.
• As an academic medical center and a National Cancer Institute-designated comprehensive cancer center, we offer the latest techniques and treatments to fight cancer and reduce side effects.
• Our academic culture and NCI comprehensive designation together earn us the opportunity to participate in clinical trials often not available elsewhere in the region. This provides patients with access to the latest clinical trials that offer hope and may lead to cures.
• We participate in early development of novel therapies, which often allow us to have patients lined up to participate in clinical trials when they open. We often have a novel therapy that may allow a patient to receive treatment, even when they have a specific treatment they want to avoid.